The National Heart Centre Singapore (NHCS) and Mayo Clinic have signed a Memorandum of Understanding (MOU) to enhance cardiovascular care and research worldwide. This collaboration, announced on 20 June 2025, follows a two-day scientific meeting supported by the Tanoto Foundation. It aims to leverage Mayo Clinic’s expertise and NHCS’s understanding of Asian cardiovascular health to develop innovative treatment paradigms.
The partnership focuses on three key areas: cardio-oncology, innovative healthcare solutions, and ageing and frailty. Cardio-oncology is crucial as cancer therapies can impact heart health, and both institutions aim to integrate cardiology and oncology expertise for optimal patient care. Mayo Clinic’s established cardio-oncology clinics and NHCS’s integrated care strategies will facilitate knowledge exchange and potential collaborations in education, research, and clinical care.
In healthcare innovation, the collaboration will explore AI-enabled digital biomarkers and cardiac imaging. NHCS will contribute its extensive cardiovascular database, including findings from the SingHEART study, to enhance AI-ECG algorithms’ performance across Asian populations.
Addressing the health of the ageing population, the partnership will focus on early identification of cardiovascular ageing using bio and digital markers, advanced imaging, and novel therapies.
Looking forward, NHCS and Mayo Clinic plan to co-develop intellectual property, clinical protocols, and guidelines to serve both Western and Asian populations. This strategic alignment aims to accelerate cardiac care innovation and empower healthcare professionals globally. Professor Yeo Khung Keong, CEO of NHCS, emphasised the importance of addressing cardiovascular disease in Asia, whilst Mayo Clinic’s Professor Amir Lerman expressed enthusiasm for the collaboration’s potential to improve global cardiovascular health.
“`
